KURA Stock News & Analysis | Latest Updates

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib) has been completed. Under Kura’s collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. (collectively, “Kyowa Kirin”), this milestone triggers a $135 million payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025.

December 2, 2025

KURA News

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology And Kyowa Kirin Report Updated Clinical Data From KOMET-007, Phase 1a/1b Trial Of Ziftomenib, In Patients With Newly Diagnosed NPM1-M And KMT2A-R AML

Kura Oncology Grants Stock Options To 5 New Hires Covering 79,200 Shares As Employment Inducement

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $28 Price Target

Kura Oncology And Kyowa Kirin Announce Phase 2 KOMET-001 Trial Results For Once-Daily Oral Menin Inhibitor Ziftomenib In Relapsed/Refractory NPM1-Mutated AML Showing 23% CR/CRh Rate, Durable MRD-Negative Responses Across Key Subgroups, Favorable Safety Wi

Reported Sunday, FDA Grants Priority Review To Kura And Kyowa Kirin's Ziftomenib NDA, Targeting First Menin Inhibitor Approval In NPM1-Mutant AML By November 30

Kura Oncology And Kyowa Kirin Reveal Monotherapy Data for Ziftomenib In Oral Presentation At The 2025 ASCO Annual Meeting

Mizuho Maintains Outperform on Kura Oncology, Lowers Price Target to $30

Kura Oncology And Kyowa Kirin Announce Combination Data For Ziftomenib In Oral Presentation At The 2025 EHA Congress

Barclays Maintains Overweight on Kura Oncology, Lowers Price Target to $11

Kura Oncology Q1 EPS $(0.66), Inline, Sales $14.11M Beat $7.73M Estimate

Uncovering Potential: Kura Oncology's Earnings Preview

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $28 Price Target

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $40 Price Target

Kura Oncology Submits New Drug Application (NDA) To The FDA For ziftomenib For The Treatment Of Acute Myeloid Leukemia (AML)

Kura Oncology to Present Kidney Cancer Drug Combo Data at AACR 2025

Kura Oncology Grants 190,000 Stock Options To Six New Employees As Inducement Awards

UBS Maintains Buy on Kura Oncology, Lowers Price Target to $14

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $40 Price Target

Kura Oncology Q4 GAAP EPS $(0.22) Beats $(0.65) Estimate, Sales $53.88M Beat $8.50M Estimate

Kura Oncology, Kyowa Kirin Enter Global Strategic Collaboration To Develop And Commercialize Ziftomenib; Kura To Receive $330M Upfront Payment And Up To $1.2B In Total Milestone Payments

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target

Cantor Fitzgerald Reiterates Overweight on Kura Oncology

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target

Kura Oncology To Present KOMET-007 Combination Trial Of Ziftomenib Data At ASH Annual Meeting

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target

Kura Oncology Q1 EPS $(0.49) Beats $(0.52) Estimate